Through our multi-year research in the anti-aging field, we have successfully completed a randomized, placebo-controlled, double-blinded, parallel human clinical trial on the anti-aging efficacy and safety of our NMN (β-Nicotinamide Mononucleotide) ingredient. Our NMN human clinical trial result has been published on GeroScience (2023) and attracted broad attention from the academic, industrial, and media world. Along the way, we have accumulated precious experience in this burgeoning and exciting field of longevity drug discovery to help people live longer and healthier, and have established a novel anti-aging drug discovery platform that focuses on maintaining the homeostasis of endogenous molecules of human body. Currently, two projects have been selected into our healthy longevity drug develop portfolio for clinical studies to treating aging-related health diseases.